AMACR and prostate cancer: Thus, six biomarkers, including ERG, AMACR, SPINK1, NKX3.1, GOLM1, and AR predict higher aggressiveness of AAM than CaM prostate cancers; then, CaM had triple-negative (ERG-negative/ETS-negative/SPINK-1-negative) disease (51% vs. 35%) [322].